B-intervention	0	8	Dressing
I-intervention	9	13	Wear
I-intervention	14	18	Time
O	19	24	after
O	25	31	Breast
O	32	46	Reconstruction
O	46	47	:
O	48	49	A
O	50	60	Randomized
O	61	69	Clinical
O	70	75	Trial
O	75	76	.

O	77	80	The
O	81	89	evidence
O	90	92	to
O	93	100	support
O	101	109	dressing
O	110	119	standards
O	120	123	for
O	124	130	breast
O	131	138	surgery
O	139	145	wounds
O	146	148	is
O	149	156	empiric
O	157	160	and
O	161	167	scarce
O	167	168	.

O	169	173	This
O	174	177	two
O	177	178	-
O	178	181	arm
O	182	192	randomized
O	193	201	clinical
O	202	207	trial
O	208	211	was
O	212	220	designed
O	221	223	to
O	224	230	assess
O	231	234	the
O	235	241	effect
O	242	244	of
O	245	253	dressing
O	254	258	wear
O	259	263	time
O	264	266	on
O	267	275	surgical
O	276	280	site
O	281	290	infection
O	291	292	(
O	292	295	SSI
O	295	296	)
O	297	302	rates
O	302	303	,
O	304	308	skin
O	309	321	colonization
O	322	325	and
O	326	333	patient
O	334	345	perceptions
O	345	346	.

O	347	348	A
O	349	354	total
O	355	357	of
B-total-participants	358	361	200
B-eligibility	362	368	breast
I-eligibility	369	375	cancer
I-eligibility	376	384	patients
I-eligibility	385	395	undergoing
I-eligibility	396	402	breast
I-eligibility	403	417	reconstruction
O	418	422	were
O	423	436	prospectively
O	437	445	enrolled
O	445	446	.

O	447	455	Patients
O	456	460	were
O	461	469	randomly
O	470	479	allocated
O	480	482	to
O	483	488	group
O	489	490	I
O	491	492	(
O	492	500	dressing
O	501	508	removed
O	509	511	on
O	512	515	the
O	516	521	first
O	522	535	postoperative
O	536	539	day
O	539	540	,
O	541	542	n
O	543	544	=
B-intervention-participants	545	548	100
O	548	549	)
O	550	552	or
O	553	558	group
O	559	561	II
O	562	563	(
O	563	571	dressing
O	572	579	removed
O	580	582	on
O	583	586	the
O	587	592	sixth
O	593	606	postoperative
O	607	610	day
O	610	611	,
O	612	613	n
O	614	615	=
B-intervention-participants	616	619	100
O	619	620	)
O	620	621	.

O	622	626	SSIs
O	627	631	were
O	632	639	defined
O	640	643	and
O	644	654	classified
O	655	664	according
O	665	667	to
O	668	676	criteria
O	677	681	from
O	682	685	the
O	686	693	Centers
O	694	697	for
O	698	705	Disease
O	706	713	Control
O	714	717	and
O	718	728	Prevention
O	728	729	.

O	730	737	Samples
O	738	747	collected
O	748	754	before
O	755	762	placing
O	763	766	the
O	767	775	dressing
O	776	779	and
O	780	785	after
O	786	787	1
O	788	791	day
O	792	793	(
O	793	798	group
O	799	800	I
O	800	801	)
O	802	805	and
O	806	807	6
O	808	812	days
O	813	814	(
O	814	818	both
O	819	825	groups
O	825	826	)
O	827	831	were
O	832	840	cultured
O	841	844	for
O	845	849	skin
O	850	862	colonization
O	863	874	assessments
O	874	875	.

O	876	884	Patients
O	885	896	preferences
O	897	900	and
O	901	912	perceptions
O	913	917	with
O	918	924	regard
O	925	927	to
O	928	934	safety
O	934	935	,
O	936	943	comfort
O	944	947	and
O	948	959	convenience
O	960	964	were
O	965	973	recorded
O	974	977	and
O	978	986	analyzed
O	986	987	.

O	988	989	A
O	990	995	total
O	996	998	of
B-total-participants	999	1002	186
O	1003	1011	patients
O	1012	1021	completed
O	1022	1025	the
O	1026	1032	follow
O	1032	1033	-
O	1033	1035	up
O	1035	1036	.

O	1037	1040	The
O	1041	1047	global
B-outcome	1048	1051	SSI
I-outcome	1052	1056	rate
O	1057	1060	was
O	1061	1062	4
O	1062	1063	.
O	1063	1064	5
O	1064	1065	%
O	1065	1066	.

B-iv-bin-abs	1067	1070	Six
O	1071	1079	patients
O	1080	1082	in
O	1083	1088	group
O	1089	1090	I
O	1091	1094	and
B-cv-bin-abs	1095	1100	three
O	1101	1103	in
O	1104	1109	group
O	1110	1112	II
O	1113	1116	had
B-outcome	1117	1120	SSI
O	1121	1122	(
O	1122	1123	p
O	1124	1125	=
O	1126	1127	0
O	1127	1128	.
O	1128	1131	497
O	1131	1132	)
O	1132	1133	.

O	1134	1140	Before
O	1141	1149	dressing
O	1149	1150	,
O	1151	1154	the
O	1155	1161	groups
O	1162	1166	were
O	1167	1174	similar
O	1175	1179	with
O	1180	1186	regard
O	1187	1189	to
B-outcome	1190	1194	skin
I-outcome	1195	1207	colonization
O	1207	1208	.

O	1209	1211	At
O	1212	1215	the
O	1216	1221	sixth
O	1222	1225	day
O	1225	1226	,
O	1227	1232	there
O	1233	1236	was
O	1237	1238	a
O	1239	1245	higher
B-outcome	1246	1258	colonization
I-outcome	1259	1261	by
I-outcome	1262	1271	coagulase
I-outcome	1271	1272	-
I-outcome	1272	1280	negative
I-outcome	1281	1294	staphylococci
O	1295	1297	in
O	1298	1303	group
O	1304	1305	I
O	1306	1307	(
O	1307	1308	p
O	1308	1309	<
O	1309	1310	0
O	1310	1311	.
O	1311	1315	0001
O	1315	1316	)
O	1316	1317	.

O	1318	1326	Patients
O	1327	1336	preferred
O	1337	1339	to
O	1340	1344	keep
O	1345	1353	dressing
O	1354	1357	for
O	1358	1361	six
O	1362	1366	days
O	1367	1368	(
O	1368	1369	p
O	1369	1370	<
O	1370	1371	0
O	1371	1372	.
O	1372	1376	0001
O	1376	1377	)
O	1377	1378	,
O	1379	1382	and
O	1383	1393	considered
O	1394	1398	this
O	1399	1400	a
O	1401	1406	safer
O	1407	1413	choice
O	1414	1415	(
O	1415	1416	p
O	1416	1417	<
O	1417	1418	0
O	1418	1419	.
O	1419	1421	05
O	1421	1422	)
O	1422	1423	.

O	1424	1431	Despite
O	1432	1437	group
O	1438	1439	I
O	1440	1443	had
O	1444	1445	a
O	1446	1452	higher
B-outcome	1453	1457	skin
I-outcome	1458	1470	colonization
O	1471	1473	by
O	1474	1483	coagulase
O	1483	1484	-
O	1484	1492	negative
O	1493	1506	staphylococci
O	1507	1509	on
O	1510	1513	the
O	1514	1519	sixth
O	1520	1533	postoperative
O	1534	1537	day
O	1537	1538	,
O	1539	1544	there
O	1545	1548	was
O	1549	1551	no
O	1552	1562	difference
O	1563	1565	in
B-outcome	1566	1569	SSI
I-outcome	1570	1575	rates
O	1575	1576	.

O	1577	1585	Patients
O	1586	1595	preferred
O	1596	1603	keeping
O	1604	1612	dressing
O	1613	1616	for
O	1617	1620	six
O	1621	1625	days
O	1626	1629	and
O	1630	1640	considered
O	1641	1643	it
O	1644	1645	a
O	1646	1651	safer
O	1652	1658	choice
O	1658	1659	.

O	1660	1674	ClinicalTrials
O	1674	1675	.
O	1675	1678	gov
O	1679	1690	NCT01148823
O	1690	1691	.
